A detailed history of Cravens & CO Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cravens & CO Advisors, LLC holds 2,208 shares of VRTX stock, worth $877,172. This represents 0.79% of its overall portfolio holdings.

Number of Shares
2,208
Previous 2,276 2.99%
Holding current value
$877,172
Previous $1.07 Billion 3.74%
% of portfolio
0.79%
Previous 0.79%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $31,280 - $34,393
-68 Reduced 2.99%
2,208 $1.03 Billion
Q2 2024

Aug 01, 2024

BUY
$392.81 - $485.53 $894,035 - $1.11 Million
2,276 New
2,276 $1.07 Billion

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cravens & CO Advisors, LLC Portfolio

Follow Cravens & CO Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cravens & CO Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cravens & CO Advisors, LLC with notifications on news.